Material Contracts with Suppliers	9 Months Ended
Mar. 31, 2019
Material Contracts with Suppliers
Material Contracts with Suppliers	Note 21. Material Contracts with Suppliers Jerome Stevens Pharmaceuticals Distribution Agreement: The Company’s primary finished goods inventory supplier through March 23, 2019 was JSP, in Bohemia, New York. Purchases of finished goods inventory from JSP accounted for approximately 40% and 37% of the Company’s inventory purchases in the three months ended March 31, 2019 and 2018, respectively. Purchases of finished goods inventory from JSP accounted for approximately 36% of the Company’s inventory purchases in the nine months ended March 31, 2019 and 2018. On August 19, 2013, the Company entered into an agreement with JSP to extend its initial contract to continue as the exclusive distributor in the United States of three JSP products: Butalbital, Aspirin, Caffeine with Codeine Phosphate Capsules USP; Digoxin Tablets USP; and Levothyroxine Sodium Tablets USP. The amendment to the original agreement extended the initial contract, which was due to expire on March 22, 2014, for five years through March 2019. In connection with the amendment, the Company issued a total of 1.5 million shares of the Company’s common stock to JSP and JSP’s designees. In accordance with its policy related to renewal and extension costs for recognized intangible assets, the Company recorded a $20.1 million expense in cost of sales, which represents the fair value of the shares on August 19, 2013. On March 23, 2019, the JSP Distribution Agreement expired and was not renewed or extended.

Note 21. Material Contracts with Suppliers

Jerome Stevens Pharmaceuticals Distribution Agreement:

The Company’s primary finished goods inventory supplier through March 23, 2019 was JSP, in Bohemia, New York. Purchases of finished goods inventory from JSP accounted for approximately 40% and 37% of the Company’s inventory purchases in the three months ended March 31, 2019 and 2018, respectively. Purchases of finished goods inventory from JSP accounted for approximately 36% of the Company’s inventory purchases in the nine months ended March 31, 2019 and 2018.

On August 19, 2013, the Company entered into an agreement with JSP to extend its initial contract to continue as the exclusive distributor in the United States of three JSP products: Butalbital, Aspirin, Caffeine with Codeine Phosphate Capsules USP; Digoxin Tablets USP; and Levothyroxine Sodium Tablets USP. The amendment to the original agreement extended the initial contract, which was due to expire on March 22, 2014, for five years through March 2019. In connection with the amendment, the Company issued a total of 1.5 million shares of the Company’s common stock to JSP and JSP’s designees. In accordance with its policy related to renewal and extension costs for recognized intangible assets, the Company recorded a $20.1 million expense in cost of sales, which represents the fair value of the shares on August 19, 2013. On March 23, 2019, the JSP Distribution Agreement expired and was not renewed or extended.